Published date: 16 October 2017

Closed future opportunity - This means that a potential contract has passed its approach to market date. A buyer can choose to consider any supplier interest or convert this notice into an opportunity ready for live procurement.


Approach to market date: 6 November 2017

Contract summary

Industry

  • Laboratory, optical and precision equipments (excl. glasses) - 38000000

Location of contract

B15 2WB

Value of contract

£300,000

Procurement reference

tender_155786/625352

Published date

16 October 2017

Approach to market date

6 November 2017

Contract start date

8 January 2018

Contract end date

7 January 2021

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No

Description

The Molecular Pathology Diagnostic Service (MPDS) is looking to advertise provision of a managed service (MSC) encompassing EGFR, BRAF, KRAS and NRAS testing over a range of cancer types.

The trust will be looking at solutions to provide equipment and reagents for the molecular testing of clinically relevant mutations in EGFR, BRAF, KRAS and NRAS from DNA extracted from formalin fixed paraffin embedded tissue and circulating tumour DNA from plasma.

There is an expectation that the FFPE DNA used in the tests above may be required in subsequent tests not covered by this managed service therefore provision for DNA extraction from FFPE material is not included within the scope of this MSC and supplied solutions for the assays required must be agnostic of DNA extraction methods used.

Extraction and testing of circulating tumour DNA from plasma for use in EGFR mutation testing will be included in the scope of the MSC.

More information

Links

About the buyer

Address

Mindelsohn Way
Birmingham
B15 2WB
England

Telephone

+44 1216978332

Email

Kirsty.Walker@uhb.nhs.uk